PDS Biotech Advances Cancer Immunotherapy with New Clinical Trial

NetScientific ( (GB:EMVC) ) has shared an update.

PDS Biotechnology, a portfolio company of EMV Capital, has initiated a Phase 3 clinical trial for its lead immunotherapy program, Versamune® HPV, targeting HPV16-positive head and neck squamous cell cancers. The trial, which aligns with FDA guidelines and includes Fast Track designation, aims to improve patient outcomes with its innovative combination therapy. Financially, PDS Biotech reported a reduced net loss for 2024, primarily due to decreased operating expenses, and announced a $22 million registered direct offering to support its clinical programs.

More about NetScientific

EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. The company focuses on generating superior returns for investors from fast-growing sectors and technologies, investing in and managing early-stage IP-rich companies. EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, supporting growth and value creation through proactive management and strategic investments.

YTD Price Performance: -15.64%

Average Trading Volume: 30,745

Technical Sentiment Signal: Buy

Current Market Cap: £11.38M

For detailed information about EMVC stock, go to TipRanks’ Stock Analysis page.